Original article—liver, pancreas, and biliary tractIncreased Mortality Among Persons Infected With Hepatitis C Virus
Section snippets
Setting
Denmark has a population of 5.4 million persons11 and an estimated 0.3% prevalence of HCV infection.12 Medical care, including antiviral treatment, is provided free of charge to all HCV-infected residents. Only an estimated 2% of Danish HCV-infected patients have been treated with interferon.13 Denmark has no awareness campaigns or population-based screening programs for HCV testing, but clinical practice is to test high-risk groups and individuals with increased liver enzyme levels and/or
Descriptive Data
Our study included 10,991 HCV-infected patients and 43,964 persons in the comparison cohort (Table 1). Among HCV-infected patients, 48% were IDUs and 11% were alcohol abusers. The corresponding percentages in the comparison cohort were 1% and 1%. HCV-infected patients had lower incomes at study inclusion, had more comorbidities, and were more likely to live in the capital of Denmark (Copenhagen) than persons in the comparison cohort. Of the HCV-infected patients, 8610 (78%) were eligible on the
Discussion
In this large-scale cohort study we studied mortality in HCV infection and observed an increased risk of death in HCV-infected patients compared with an age- and sex-matched population-based comparison cohort. The increased risk of death was most pronounced in the younger HCV-infected patients and during the first year of follow-up evaluation, and the estimated effect of HCV infection on mortality was confounded by other prognostic factors. The excess mortality in the younger HCV-infected
References (38)
- et al.
Viral hepatitis C
Lancet
(2003) - et al.
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study
Lancet
(2006) - et al.
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study
J Hepatol
(2001) - et al.
Market uptake of new antiviral drugs for the treatment of hepatitis C
J Hepatol
(2008) - et al.
Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study
J Hepatol
(2010) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality
J Clin Epidemiol
(2004) - et al.
Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany—a 25-year multicenter study
J Hepatol
(2005) - et al.
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Lancet
(1997) - et al.
Rate of natural disease progression in patients with chronic hepatitis C
J Hepatol
(2003)
Outcome of hospital care of liver disease associated with hepatitis C in the United States
Hepatology
Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model
J Hepatol
Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C
Hepatology
The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance
Am J Gastroenterol
Clinical course of hepatitis C virus during the first decade of infection: cohort study
BMJ
Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study
Gut
Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study
J Viral Hepat
45-Year follow-up of hepatitis C virus infection in healthy young adults
Ann Intern Med
Obstacles to successful HCV treatment in substance addicted patients
J Addict Dis
Cited by (40)
Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens
2019, Clinical Gastroenterology and HepatologyInternational therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement
2017, Autoimmunity ReviewsCitation Excerpt :HCV-EHMs include many diseases with B-lymphoproliferative and/or autoimmune the most documented and frequent [1]. The recent availability of mortality rates in large cohorts of subjects confirmed the association of HCV infection with many extrahepatic pathological conditions including cardiovascular, neurologic, metabolic or renal diseases and extra-hepatic tumors [2–9]. The comparison between patients with persisting HCV infection and those who cleared the virus, showed that viral eradication significantly reduced the rate of extra-hepatic deaths [2,5,10,11].
New insights into HCV-related rheumatologic disorders: A review
2017, Journal of Advanced ResearchCitation Excerpt :The main cause of mortality in HCV infected patients is the liver disease [107–113]. However, HCV infected patients showed increased mortality rates due to extra-hepatic complications (i.e., cardiovascular, renal, tumoral) [111,112,114–116]. Some chronic infections have been suggested as triggers for cardiovascular diseases [117–119].
Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients
2015, Journal of Clinical VirologyCitation Excerpt :Infection by hepatitis C virus (HCV) becomes persistent in around 80% of cases and in turn a major cause of liver disease for the approximately 184 million HCV patients worldwide. Chronically infected patients are at risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) [1]. HCV is a single-strand RNA virus belonging to the Flaviviridae family.
Extrahepatic manifestations of chronic hepatitis C virus infection
2014, Digestive and Liver DiseaseCitation Excerpt :Most studies have found liver disease to be the primary cause of mortality in HCV infected patients [92–98]. HCV infection also showed a higher mortality rate for extra-hepatic complications (i.e., cardiovascular, renal, tumoural) [96,97,99,100]. The study by Lee and colleagues attributed to serum HCV RNA positivity a significantly higher mortality risk from non-liver-related causes [96].
Fracture risk in hepatitis C virus infected persons: Results from the DANVIR cohort study
2014, Journal of HepatologyCitation Excerpt :We used the unique 10-digit civil registration number assigned to all Danes at birth or immigration [14] to link the following data sources: HCV-exposed patients were identified from the DANVIR cohort, which comprises all patients tested for HCV in 14 of the 18 laboratories that perform such testing in Denmark [15,16]. DANVIR data includes results and dates of HCV antibody tests (from 1991 onward) and HCV RNA tests (from 1995 onward).
Conflicts of interest These authors disclose the following: Niels Obel received funding from Roche, Bristol-Meyers Squibb, Merck Sharp & Dohme, GlaxoSmithKline, Abbott, Boehringer Ingelheim, Janssen-Cilag, and Swedish-Orphan Drugs; and Peer Brehm Christensen received funding from Roche and Schering-Plough. The remaining authors disclose no conflicts.
Funding The study was funded by a PhD scholarship from Rigshospitalets Research Council (L.H.O.).